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sclerotic features (p<.0001). Restriction in ROM at most
severely affected joints was greater in patients with sclerotic
features compared to those without observable sclerotic
changes (p<0.0001). JFS-positive patients with sclerotic
features were more likely to have self-reported limitations in
joint movement (p<0.001). In those with isolated joint
involvement, ankles (88%) and shoulders (44%) were most
frequently affected. In multivariable analysis, shorter dura-
tion of cGVHD, less impairment in measured ROM and lower
maximum individual organ score were able to identify 77% of
patients with positive JFS without sclerotic features.
Conclusion: Although JFS involvement is common in cGVHD,
the incidence of joint involvement in the absence of detect-
able skin or fascial sclerosis is low. Future reﬁnements of the
NIH criteria may need to recognize separately joint re-
strictions that occur without evidence of sclerotic involve-
ment within the JFS NIH scale.423
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Background: Sclerotic-type chronic graft versus host disease
(Scl-cGVHD) is a late manifestation of cGVHD that can lead to
signiﬁcant functional disability and morbidity. Scl-cGVHD is
often refractory to treatment and its pathogenesis remains
poorly understood. Recent studies on a murine model of Scl-
cGVHD have proposed that regulatory B cells (Breg) may play
a role in controlling development of early T cell inﬁltrates
and later skin ﬁbrosis skin. Although cGVHD has been asso-
ciated with the presence of autoantibodies, elevated B cell
activation factor, and increases in atypical B cell populations,
alterations in Breg populations have not been explored. We
therefore examined Breg populations in a cohort of severe
Scl-cGVHD patients with sclerotic changes affecting > 50%
body surface area (BSA).
Patients and Methods: In humans, two B cell populations
have been identiﬁed as capable of producing IL-10 and having
suppressive activity: B10 cells (CD27+CD24+) and B1 cells
(CD24+CD38++). CD1dhiCD5+ B cells (B10 pro) were also
described as the source of IL10. We assessed the expression of
CD1d, CD5, CD24, CD39, CD43, CD27 and CD38 on B cells in
peripheral blood of patients enrolled in a cross-sectional nat-
ural history studyof cGVHD (clinicaltrials.gov#NCT00331968).
P values comparing populations were determined using
Mann-Whitney nonparametric analyses.
Results: B cells in 25 patients with severe Scl-cGVHD (me-
dian affected BSA¼65%) were compared to cGVHD patients
without cutaneous sclerosis (n¼6), and to allogeneic trans-
plant patients without cGVHD (n¼7). Patients were assessed
at a median of 4 years after transplant and amedian duration
of 3 years of cGVHD. The overall frequency of CD19+ B cellswas comparable in cGVHD and non-cGVHD patients. B10 B
cells (CD27+CD24+) were signiﬁcantly diminished in Scl-
cGVHD when compared to nonScl-cGVHD (4.6 vs. 7.0%,
p¼.022), as well as to non-cGVHD (4.6 vs. 8.2% p¼0.026). B10
pro population (CD1d+CD5+) in Scl-cGVHD were signiﬁ-
cantly diminished only relative to nonScl-cGVHD (4.5 vs.
7.5%, p¼.014). B1 B cells (CD24+CD38++) were not different
from the other groups. Finally, we further compared patients
with active cGVHD (n¼22) and found signiﬁcantly decreased
B10 cells compared to patients with stable disease, (4 vs. 9%,
p<0.0001).
Conclusion: A reduced frequency of Breg populations was
observed in Scl-cGVHD patients, and this reduction was
associated with active cGVHD. Functional analysis is neces-
sary to validate a regulatory role of B1 and B10 B cell subsets
in Scl-cGVHD.424
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Bacterial septicemia is a leading cause of mortality following
AlloHCT. A few studies have reported a higher incidence of
BSI in patients with aGVHD, supporting the theory that
aGVHD is associated with an increased risk of infection. The
aim of our study was to evaluate the relationship between
the presence of gut aGVHD and the subsequent development
of EB-BSI.
In this retrospective study, EB-BSI (enterococci and gram-
negative rods) data was collected between day 0 and day
+180 following AlloHCT, The incidence rates of EB-BSI were
compared before and after the onset of gut aGVHD. Two
hundred sixty four children underwent AlloHCT for malig-
nant (n¼162, 61.4%) and non-malignant (n¼102, 38.6%) dis-
orders between 2000-2012. Median age was 9 years, M/F
ratio was 64/36%, and donor sources included matched
family donors (n¼107, 40%) and matched unrelated donors
(n¼157, 60%). Patients were conditioned with either mye-
loablative (n¼122, n¼46%), reduced toxicity (n¼66, 25%), or
reduced intensity (n¼76, 29%) regimens. Additionally, a
subset of the patients received alemtuzumab (n¼71, 27%) or
rabbit ATG (n¼134, 51%).
The groups of patients with EB-BSI (n¼122, 46.2%) and
without EB-BSI (n¼142, n¼53.8%) were comparable (age,
p¼0.18; sex, p¼0.8, disease type, p¼0.13; donors, p¼0.26;
conditioning regimen, p¼0.19; use of alemtuzumab, p¼0.8
and ATG, p¼0.4). The overall incidence of aGVHD was 44%
(n¼115), including both gut aGVHD (28%) and non-gut
aGVHD (16%). The incidences of grades II, III and IV gut
aGVHD were 48.7%, 48.7% and 2.7%, respectively.
If the development of gut aGVHD is a risk factor for devel-
opment of EB-BSI, we reasoned that there should be a tem-
poral relationship between onset of aGVHD and infection.
We therefore calculated the infection density both before
and after the onset of gut aGVHD, by dividing the number of
episodes of EB-BSI during each time period by the total
number of patient-days in that time period multiplied by
1000. Prior to the onset of gut aGVHD, the infection density
was 2.4 infections/1000 person-days. After onset of gut
